Allogene’s CAR T-cell Therapy Triggers Durable Anti-Tumor Response in Animal Model
ALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can…
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreWhile myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreALLO-715, Allogene Therapeutics‘ donor-derived CAR T-cell therapy, can…
A triple regimen composed of Kyprolis (carfilzomib),…
Bluebird bio has officially opened a facility in…
Maintenance therapy with Ninlaro (ixazomib) can prolong…
Aiming to improve lenalidomide‘s safety and efficacy, ChemioCare…
The Multiple Myeloma Research Foundation (MMRF) has launched…